Skip to main content

Advertisement

Figure 2 | BMC Infectious Diseases

Figure 2

From: Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors

Figure 2

a: Hazard ratios (95% CI) of risk factors for clinical deterioration during 24 weeks of antituberculosis (TB) treatment in 292 patients (Cox proportional hazards model) and Figure 2b>: Hazard ratios (95% CI) of risk factors for clinical deterioration during 24 weeks of TB treatment in 206 HIV-1 infected patients* (Cox proportional hazards model).

*CD4 count not performed in 3 of 209 HIV-1 infected patients

(1) Microbiologic confirmation with drug susceptibilities known at TB diagnosis

(2) CD4 strata used: Stratum 1 = CD4+ > 350 cells/ μL, stratum 2 = CD4+ from 200 – 350 cells/ μL, stratum 3 = CD4+ < 200 cells/ μL;

(3) TMP-SMX chemoprophylaxis = Trimethoprim sulfamethoxazole 160/800mg daily

(4) Antiretroviral treatment regimens as follows: D4T/3TC/EFV (89), D4T/3TC/NVP (3), AZT/3TC/EFV (13), AZT/3TC/NVP (2), TDF/3TC EFV (2); D4T= stavudine 30mg twice daily, 3TC = lamivudine 150mg twice daily, EFV = efavirenz 600mg nocte, AZT = zidovudine 300mg twice daily, NVP = nevirapine 200mg twice daily, TDF = tenofovir 300mg daily

TB = tuberculosis, DST = drug susceptibility testing, ART = antiretroviral treatment, P = p-value (significant if < 0.05), 95% CI = 95% confidence interval

Back to article page